LDLR and glioblastoma: Finally, we confirmed variable levels of detectable LDLR expression in adult (GIN28) and paediatric (SF188, KNS42) GBM in vitro cell lines, thus rendering these lines as future tools to test LDLR-targeted nanotherapy delivery.